What's Happening?
Amgen has developed a subcutaneous formulation of its thyroid eye disease (TED) drug, Tepezza, which has shown promising results in a late-stage trial. This new formulation corrected abnormal eye protrusion as effectively as the currently approved intravenous
version. Analysts suggest that this could provide a commercial boost for the therapeutic antibody. The subcutaneous version, administered via Amgen's on-body injector technology, achieved a 76.7% proptosis response rate over 24 weeks, compared to 19.6% for placebo. This significant treatment effect could help the Tepezza franchise return to growth, as sales had dipped slightly in the fourth quarter of 2025. The new formulation also showed improvements in secondary outcomes such as diplopia and quality of life.
Why It's Important?
The introduction of a more convenient subcutaneous formulation of Tepezza could significantly impact the market for thyroid eye disease treatments. With the potential for self-administration, this formulation may increase patient adherence and expand the market, which has been stagnant. The convenience of the on-body injector could become a central consideration for patients and healthcare providers. This development positions Amgen to potentially capture a larger share of the TED market, especially as it competes with Viridian Therapeutics' drug candidate, elegrobart. The success of this formulation could lead to increased revenues and a stronger market presence for Amgen.
What's Next?
Amgen's new formulation of Tepezza is expected to undergo further evaluations and potential regulatory reviews. The company may focus on demonstrating the ease of use and efficacy of the on-body injector to gain market acceptance. As the TED market evolves, Amgen will likely continue to monitor competitor developments, particularly those of Viridian Therapeutics. The outcome of these efforts could influence future marketing strategies and partnerships. Additionally, the company may explore further innovations in drug delivery to maintain a competitive edge.
